Share this video  

ASCO 2021 | CheckMate 648: 1L IO-IO in advanced esophageal squamous cell carcinoma

Ian Chau, MD, FRCP, Royal Marsden NHS Foundation Trust, London, UK, presents the first results of the CheckMate 648 study (NCT03143153), a Phase III study evaluating nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC). Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival versus chemotherapy alone, along with durable objective responses and acceptable safety in patients with ESCC, and each represents a new first-line treatment option. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.